Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study / Passamonti F.; Palandri F.; Saydam G.; Callum J.; Devos T.; Guglielmelli P.; Vannucchi A.M.; Zor E.; Zuurman M.; Gilotti G.; Zhang Y.; Griesshammer M.. - In: THE LANCET. HAEMATOLOGY. - ISSN 2352-3026. - ELETTRONICO. - 9:(2022), pp. e480-e492. [10.1016/S2352-3026(22)00102-8]

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study

Guglielmelli P.
Writing – Original Draft Preparation
;
Vannucchi A. M.
Writing – Original Draft Preparation
;
2022

Abstract

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
2022
9
e480
e492
Passamonti F.; Palandri F.; Saydam G.; Callum J.; Devos T.; Guglielmelli P.; Vannucchi A.M.; Zor E.; Zuurman M.; Gilotti G.; Zhang Y.; Griesshammer M.
File in questo prodotto:
File Dimensione Formato  
Passamonti_Lancet Haematology 2022.pdf

Accesso chiuso

Licenza: DRM non definito
Dimensione 616.37 kB
Formato Adobe PDF
616.37 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1286306
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact